NeoStem Clarification: No New Securities Being Issued
June 12 2014 - 7:15PM
NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular
therapy industry, is issuing this press release to clarify for
shareholders that NeoStem is not engaged in a new financing. The
registration statement filed today is merely a renewal of an
outstanding registration statement covering the issuance of shares
underlying warrants that were issued in 2011 and 2012 and remain
outstanding. The underlying shares were previously registered, but
the registration statement is expiring under SEC rules and needs to
be refreshed.
No new securities are being offered by NeoStem.
About NeoStem
NeoStem is a leader in the emerging cellular therapy industry,
pursuing the preservation and enhancement of human health globally
through the development of cell based therapeutics that prevent,
treat or cure disease by repairing and replacing damaged or aged
tissue, cells and organs and restoring their normal function. The
business includes the development of novel proprietary cell therapy
products as well as a revenue-generating contract development and
manufacturing service business. This combination has created an
organization with unique capabilities for cost effective in-house
product development and immediate revenue and cash flow generation.
www.neostem.com
CONTACT: Investor Contact:
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Phone: +1-646-597-6979
Email: mrice@lifesciadvisors.com
Media Contact:
NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jul 2023 to Jul 2024